Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
Date:3/6/2013

NEW YORK, March 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax" or the "Company") (NasdaqGS: IPXL). The investigation focuses on whether the Company and its executives violated federal securities laws.

On March 4, 2013, Shares of Impax dropped $4.10, or 20.5 percent, to $15.90 in aftermarket trading following the Company's announcement that the FDA issued a new Form 483 with twelve observations, three of which are designated as repeat observations from past inspections. New and pending applications that relate to the Hayward, California manufacturing facility may be withheld by the FDA until the Form 483 problems are solved. The FDA sent Impax a warning letter in January 2011 based on an inspection of the Hayward, Calif., plant, and found other problems in a March 2012 inspection. The March 2012 inspection, the FDA said the original problems had been addressed, but it found problems in its quality control laboratory. Shares of Impax stock were down over 25% in early trading on March 5, 2013 from its prior days close. 

If you are aware of any facts relating to this investigation, or purchased shares of Impax, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman , 212-697-6484
eitan@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
5. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... people living in Santa Clara County, CA ... B on the Santa Clara University campus. CVS Pharmacy ... to protect patients against the disease. Students at Santa ... to get vaccinated. In addition, anyone who has had ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. (OTC/QB: ... OXS-1550, was described as a "clinical trial triumph" after ... went into complete cancer remission. Daniel ... Minnesota Masonic Cancer Center. --> Daniel ... Minnesota Masonic Cancer Center. --> An ...
(Date:2/10/2016)... 2016  LexisNexis® Risk Solutions, a leading provider ... launch of LexisNexis Provider Performance Monitor , ... and optimize the quality and efficiency of provider ... scores. By measuring provider performance through Provider Performance ... better outcomes, improve the patient experience and reduce ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis ... Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... memory. The book’s publication date is March 16, 2016. A free review copy ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... and most versatile series of monitor mounts ever. , “Our goal was to ... and easy to install system that we have ever created.” said Darren Hulsey, Product ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
Breaking Medicine News(10 mins):